INTRODUCTION:

Omeprazole plays a pivotal role in the treatment of peptic ulcers, GERD, and other gastrointestinal conditions. However, its therapeutic efficacy is compromised by its limited solubility, impacting its absorption and bioavailability. This article aims to explore and evaluate recent strategies employed to enhance the solubility of omeprazole, thus improving its clinical effectiveness.¹

Omeprazole, a proton pump inhibitor (PPI), has emerged as a cornerstone in the treatment of various gastrointestinal conditions. Introduced in the late 1980s, it revolutionized the management of acid-related disorders, offering a potent and selective means to inhibit gastric acid secretion.²Omeprazole's primary therapeutic indications include the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome.³

Mechanisum of action:

At the molecular level, omeprazole exerts its pharmacological effects by irreversibly inhibiting the H+/K+ ATPase proton pump in the parietal cells of the stomach lining. This inhibition leads to a significant reduction in gastric acid secretion, effectively alleviating symptoms and promoting the healing of acid-related disorders. The specificity of omeprazole for the proton pump sets it apart as a potent and targeted therapeutic agent.⁴

Clinical Significance:

The clinical significance of omeprazole lies not only in its efficacy in managing acid-related disorders but also in its role in preventing complications such as oesophageal strictures, Barrett's oesophagus, and even certain gastrointestinal cancers associated with chronic acid exposure. The widespread use of omeprazole has contributed to improved patient outcomes and enhanced quality of life for individuals suffering from these conditions.^5,6

Formulations and Dosage:

Omeprazole is available in various formulations, including delayed-release capsules, oral suspensions, and intravenous formulations, allowing for flexibility in administration based on patient needs and preferences. Standard dosages are tailored to the specific condition being treated, with variations depending on the severity of symptoms and the duration of therapy.⁸

Challenges in Omeprazole Formulation:

Despite its clinical success, omeprazole presents a significant formulation challenge due to its poor water solubility.⁹ This limitation hinders its efficient dissolution in the gastrointestinal tract, potentially impacting its bioavailability and therapeutic efficacy. Addressing this challenge has become a focal point of pharmaceutical research,^10,11leading to the exploration of various solubility enhancement strategies to optimize omeprazole formulations.¹²

Scope of Review:

This review aims to comprehensively explore and evaluate diverse strategies employed to enhance the solubility of omeprazole. By delving into solid dispersion technology, nanosizing techniques, cyclodextrin complexation, salt formation, and micellar delivery systems, we seek to provide a nuanced understanding of the advancements in pharmaceutical science geared towards overcoming the solubility challenges associated with omeprazole. The subsequent sections will critically analyse each strategy, considering mechanisms, comparative effectiveness, stability concerns, and future directions, ultimately contributing to the broader landscape of drug delivery optimization for omeprazole and other poorly water-soluble drugs.^13-16

Solid Dispersion Technology:

Principles:

Solid dispersion technology has emerged as a powerful strategy to enhance the solubility of poorly water-soluble drugs, including omeprazole.¹⁷ The fundamental principle involves dispersing the drug within a hydrophilic carrier, typically a polymer, to improve its wettability, dissolution, and, consequently, bioavailability.

Mechanisms of Solid Dispersion:

The process of solid dispersion begins with the selection of a suitable hydrophilic carrier, such as polyvinylpyrrolidone (PVP) or hydroxypropyl methylcellulose (HPMC). These carriers have high water solubility and can effectively encapsulate hydrophobic drugs like omeprazole.¹⁷ The drug-carrier mixture is then processed through various methods, such as hot melt extrusion or spray drying, to obtain a homogenous dispersion.During solid dispersion, the hydrophilic carrier envelops the omeprazole particles, creating a system where drug molecules are more readily available for dissolution.¹⁸ This enhances the drug's contact with the aqueous environment upon administration, leading to improved dissolutionkinetics.^19,20

Impact on Wettability and Dissolution:

One of the key advantages of solid dispersion technology is its ability to address the low wettability of poorly water-soluble drugs. Omeprazole, being hydrophobic, tends to resist wetting by aqueous fluids in the gastrointestinal tract. Solid dispersions alter this behaviour by promoting rapid and uniform wetting of omeprazole particles.²¹The hydrophilic carrier's presence ensures that the drug particles disperse evenly, creating a larger surface area available for interaction with gastrointestinal fluids. Improved wettability directly influences the dissolution rate of omeprazole. As the drug particles become more readily wetted, the barriers to dissolution are minimized.²²Consequently, the dissolution process is accelerated, leading to increased concentrations of omeprazole in the gastrointestinal fluids and, ultimately, improved bioavailability.^20-23

Applications of Solid Dispersion in Omeprazole Formulations:

Solid dispersion technology has found widespread application in the formulation of omeprazole dosage forms.²³Various studies have investigated the incorporation of omeprazole into solid dispersions to enhance its therapeutic performance. Solid dispersions can be incorporated into tablets, capsules, or other oral dosage forms, offering versatility in drug delivery.²⁴

Additionally, the choice of the hydrophilic carrier plays a crucial role in determining the characteristics of the solid dispersion. For example, PVP-based solid dispersions have been shown to exhibit excellent solubility enhancement for omeprazole, making them suitable candidates for further development in pharmaceutical formulations.²⁵

Advantages:

· Enhanced Bioavailability: The primary advantage of solid dispersion technology for omeprazole lies in its ability to significantly enhance drug bioavailability. By addressing the challenges associated with poor solubility, solid dispersions ensure that a larger fraction of the administered dose reaches the systemic circulation.²⁶ This, in turn, maximizes the therapeutic effect of omeprazole in the treatment of gastrointestinal disorders.²⁷

· Improved Stability: Solid dispersions can contribute to the improved stability of omeprazole. The amorphous nature of drug molecules within the dispersion can reduce the likelihood of crystallization, a common issue with poorly water-soluble drugs. This enhanced stability is particularly valuable in ensuring the long-term efficacy of omeprazole formulations.²⁸

· Tailored Release Profiles: The versatility of solid dispersion technology allows for the development of formulations with tailored release profiles. This is essential for drugs like omeprazole, where controlled release can optimize therapeutic outcomes. Depending on the choice of the hydrophilic carrier and the manufacturing process, solid dispersions can be designed to release omeprazole in a sustained manner, prolonging its presence in the gastrointestinal tract.²⁹

· Potential for Combination Therapies: Solid dispersions provide a platform for combining omeprazole with other drugs in a single dosage form. This is particularly relevant in the treatment of complex conditions where multiple therapeutic agents are required.³⁰The homogenous distribution of omeprazole and other active ingredients within the solid dispersion can lead to synergistic effects and improved patient compliance.³¹

Future Directions and Challenges:

· Exploration of Novel Hydrophilic Carriers: While PVP and HPMC have demonstrated success in enhancing omeprazole solubility, ongoing research is exploring the use of novel hydrophilic carriers. This includes natural polymers and innovative synthetic materials, each with its own set of advantages and challenges. Future formulations may harness the unique properties of these carriers to further optimize omeprazole delivery.³²

· Process Optimization: The optimization of manufacturing processes for solid dispersions is an area of continuous improvement. Fine-tuning parameters such as extrusion temperature, polymer-drug ratio, and the choice of solvents can influence the characteristics of the resulting solid dispersion. Further research is needed to identify optimal conditions that ensure reproducibility, scalability, and cost-effectiveness in large-scale production.³³

· In Vivo Studies and Clinical Translation: While in vitro studies have demonstrated the efficacy of solid dispersion technology in enhancing omeprazole solubility, translating these findings into clinical success requires comprehensive in vivo studies. Clinical trials evaluating the safety, efficacy, and patient outcomes associated with omeprazole solid dispersions will be pivotal in establishing the technology's viability in real-world applications.³⁴

Solid dispersion technology stands as a promising strategy for overcoming the solubility challenges of omeprazole. By enhancing wettability, dissolution, and bioavailability, solid dispersions offer a multifaceted approach to optimizing the therapeutic performance of omeprazole formulations. As research in this field progresses, further innovations and refinements in solid dispersion technology are expected, contributing to the development of more effective omeprazole dosage forms for improved patient outcomes in the treatment of gastrointestinal disorders.³⁵

Nanosizing Techniques:

1. Nanocrystals:

Nanosizing techniques have emerged as innovative strategies to address the solubility challenges associated with poorly water-soluble drugs, such as omeprazole.³⁶Nanocrystals, a prominent nanosizing approach, involve reducing the particle size of drug particles to the nanometre range. This reduction in size enhances the surface area and, consequently, the dissolution rate, offering a promising solution to improve bioavailability.³⁷

Nanocrystal Formation Mechanisms:

Nanocrystals can be produced through various methods, including bottom-up processes such as precipitation and top-down processes like high-pressure homogenization or wet milling. In the case of omeprazole, these methods aim to break down larger drug particles into nanosized entities, creating a more uniform and dispersible drug formulation.³⁸

Impact on Dissolution Kinetics:

The primary advantage of nanocrystals lies in their ability to significantly improve the dissolution kinetics of poorly water-soluble drugs. Omeprazole, known for its low solubility, benefits from nanosizing as the increased surface area allows for more efficient interaction with the dissolution medium. This results in a faster and more complete release of omeprazole in the gastrointestinal tract, overcoming the limitations associated with traditional formulations.³⁹

2. Nanoemulsions:

Formulation of Nanoemulsions:

Nanoemulsions represent another nanosizing technique with promising applications in enhancing drug solubility. These are colloidal dispersions of oil and water stabilized by an emulsifying agent. The nanoscale droplets in nanoemulsions provide a large interfacial area,facilitating improved solubilization of lipophilic drugs like omeprazole.⁴⁰

Role in Enhancing Bioavailability:

Nanoemulsions offer several advantages in terms of bioavailability enhancement for omeprazole. The small droplet size ensures a larger surface area available for drug absorption, facilitating rapid and efficient uptake in the gastrointestinal tract. Additionally, the emulsifying agents used in nanoemulsions can contribute to improved drug stability and prolonged release, further optimizing therapeutic outcomes.⁴¹

Comparative Analysis of Nanosizing Techniques for Omeprazole:

· Efficacy in Solubility Enhancement: Several studies have compared the efficacy of nanocrystals and nanoemulsions in enhancing the solubility of omeprazole. While both techniques have demonstrated success, variations in particle size distribution, stability, and manufacturing processes have been reported. Understanding the nuances of each technique is crucial for tailoring formulations to the specific requirements of omeprazole.⁴²

· Considerations for Formulation Development: Formulating nanosized drug delivery systems require careful consideration of various factors, including the choice of stabilizers, surfactants, and processing methods. Each parameter can influence the characteristics of the final formulation, affecting stability, drug release, and overall performance. Researchers and formulators must strike a balance between maximizing solubility enhancement and ensuring the practicality and scalability of the manufacturing process.⁴³

Future Directions and Challenges:

· Advances in Nanosizing Technologies: Continued research in nanosizing technologies is expected to yield further advancements. Novel techniques, such as supercritical fluid technology and electrospinning, are being explored for their potential in producing nanosized drug formulations. These approaches may offer additional benefits in terms of reproducibility, scalability, and ease of manufacturing.⁴⁴

· Overcoming Stability Challenges: Stability remains a critical consideration in the development of nanosized drug formulations. The high surface energy associated with nanosized particles can lead to increased aggregation and potential stability issues. Ongoing research is focused on identifying stabilizers and formulation strategies to mitigate these challenges and ensure the long-term stability of nanosized omeprazole formulations.⁴⁵

· In Vivo Studies and Clinical Translation: While in vitro studies have provided valuable insights into the solubility enhancement potential of nanosizing techniques for omeprazole, translating these findings into clinical success requires comprehensive in vivo studies. Clinical trials evaluating the safety, efficacy, and patient outcomes associated with nanosized omeprazole formulations will be crucial in determining the feasibility of these technologies in real-world applications.⁴⁶

Nanosizing techniques, including nanocrystals and nanoemulsions, offer promising solutions to enhance the solubility and bioavailability of omeprazole. By leveraging the principles of nanotechnology, these approaches address the limitations posed by omeprazole's poor water solubility, providing a pathway for more effective and patient-friendly formulations. As research in nanosizing technologies continues to progress, further refinements, innovations, and successful clinical translations are anticipated, ushering in a new era of advanced drug delivery systems for omeprazole and other poorly water-soluble drugs.⁴⁷

Cyclodextrin Complexation:

Cyclodextrins (CDs) have gained prominence as versatile carriers for enhancing the solubility of poorly water-soluble drugs, and omeprazole is no exception. Cyclodextrins are cyclic oligosaccharides with a hydrophilic outer surface and a hydrophobic cavity, allowing them to form inclusion complexes with a variety of guest molecules, including hydrophobic drugs.⁴⁸

Mechanisms of Cyclodextrin Complexation:

In the case of omeprazole, cyclodextrins can form inclusion complexes by encapsulating the hydrophobic portion of the drug within their cavities, shielding it from the aqueous environment.⁴⁹This inclusion complexation increases the apparent solubility of omeprazole in water, promoting its release and absorption in the gastrointestinal tract.⁵⁰

Types of Cyclodextrins for Omeprazole Complexation:

Different cyclodextrins, such as α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin, have been investigated for their ability to form inclusion complexes with omeprazole. The selection of the cyclodextrin type depends on factors such as the size of the drug molecule and the specific interactions desired between the drug and the carrier.⁴⁹

Stability and Bioavailability:

· Enhanced Solubility and Dissolution: Cyclodextrin complexation significantly enhances the solubility of omeprazole by forming a water-soluble inclusion complex. The hydrophobic drug molecules are encapsulated within the hydrophobic cavity of the cyclodextrin, shielding them from the aqueous environment.⁵¹ This process results in improved wettability and dissolution of omeprazole, addressing the challenges posed by its poor water solubility.⁵²

· Impact on Bioavailability: The improved solubility and dissolution kinetics achieved through cyclodextrin complexation have direct implications for omeprazole's bioavailability.⁵³ By enhancing the drug's release and absorption, cyclodextrin inclusion complexes contribute to a more efficient utilization of the administered dose, ultimately improving the therapeutic efficacy of omeprazole in the treatment of gastrointestinal disorders.⁵⁴

Applications of Cyclodextrin Complexation:

· Formulation Development: Cyclodextrin complexation has found applications in various pharmaceutical formulations, including tablets, capsules, and liquid formulations. The versatile nature of cyclodextrins allows for the development of different dosage forms tailored to specific patient needs and preferences.⁵⁵

· Combination Therapies: The ability of cyclodextrins to form inclusion complexes with multiple drugs opens avenues for combination therapies. This is particularly relevant in cases where a synergistic effect between omeprazole and another therapeutic agent is desired.⁵⁶ Cyclodextrin-based formulations can facilitate the co-delivery of multiple drugs, enhancing patient compliance and therapeutic outcomes.

Challenges and Considerations:

· Guest-Host Interaction Specificity: The success of cyclodextrin complexation depends on the specificity of interactions between the guest molecule (omeprazole) and the host molecule (cyclodextrin).⁵⁷The choice of the appropriate cyclodextrin and understanding the molecular characteristics of omeprazole are crucial in optimizing complexation efficiency.

· Stability of Inclusion Complexes: The stability of cyclodextrin inclusion complexes is a critical consideration. Factors such as pH, temperature, and the presence of co-solvents can influence the stability of these complexes. Formulation scientists must carefully assess these parameters to ensure the long-term stability of cyclodextrin-based omeprazole formulations.⁵⁸

Future Directions:

· Development of Modified Cyclodextrins: Ongoing research focuses on the development of modified cyclodextrins to enhance their solubilizing capabilities and improve the specificity of guest-host interactions. These modified cyclodextrins may offer superior performance in forming inclusion complexes with omeprazole, paving the way for more effective formulations.^59,60

· Exploring Combination Approaches: Combining cyclodextrin complexation with other solubility enhancement strategies, such as nanosizing or solid dispersion, is an area of increasing interest.⁶¹Such combination approaches aim to capitalize on the strengths of different techniques, providing synergistic effects for optimizing omeprazole formulations.

Cyclodextrin complexation has proven to be a valuable strategy in enhancing the solubility and bioavailability of omeprazole. By forming inclusion complexes, cyclodextrins mitigate the challenges associated with omeprazole's poor water solubility, offering a versatile platform for formulation development. As research in cyclodextrin-based drug delivery continues to evolve, the optimization of inclusion complexation techniques and the exploration of novel cyclodextrin derivatives hold the promise of further improving omeprazole formulations and advancing the treatment of gastrointestinal disorders.

Salt Formation:

Salt formation represents a fundamental approach in pharmaceutical chemistry for improving the solubility and dissolution characteristics of poorly water-soluble drugs, and omeprazole has been a subject of interest in this context. The process involves converting the acidic or basic drug into a salt form by reacting it with an appropriate counterion.⁶²In the case of omeprazole, the formation of salts, such as omeprazole sodium, has been explored as a strategy to overcome its intrinsic solubility limitations.

Mechanism of Salt Formation:

The mechanism of salt formation involves the interaction between the ionizable groups of the drug molecule and a counterion. In the case of omeprazole, which contains a weakly basic pyridine nitrogen, the conversion to a salt involves protonation of the nitrogen by a strong acid, typically resulting in the formation of a more water-soluble salt.⁶³

Types of Counterions for Omeprazole:

The choice of counterion is crucial in salt formation, as it influences the properties of the resulting salt.⁶⁴ Omeprazole sodium, for example, is a commonly investigated salt form, and its stability, solubility, and impact on dissolution kinetics are of particular interest in pharmaceutical research.

Impact on Solubility:

· Enhanced Aqueous Solubility: The primary objective of salt formation in the context of omeprazole is to enhance its aqueous solubility. The conversion to a salt introduces ionizable groups that interact more favourably with water molecules, leading to increased solubility.⁶⁵ Omeprazole sodium, in particular, has demonstrated significantly improved solubility compared to the parent drug, making it a promising alternative for formulation development.

· Influence on Dissolution Profiles: The enhanced solubility of omeprazole salts translates directly into improved dissolution profiles. The salt form exhibits faster dissolution rates, ensuring a more rapid release of the drug in the gastrointestinal tract. This is particularly advantageous for drugs like omeprazole, where timely dissolution is critical for optimal therapeutic outcomes.⁶⁶

Comparative Analysis with Other Strategies:

· Solid Dispersion and Nanosizing vs. Salt Formation: Comparing salt formation with other solubility enhancement strategies, such as solid dispersion and nanosizing, provides insights into their relative advantages and limitations. While solid dispersion and nanosizing focus on physical modifications of the drug, salt formation involves a chemical transformation. The choice between these strategies depends on factors such as the nature of the drug, the desired release profile, and considerations for formulation development.⁶⁷

· Cyclodextrin Complexation vs. Salt Formation: Similarly, comparing salt formation with cyclodextrin complexation reveals differences in their mechanisms and outcomes. While both strategies aim to improve drug solubility, salt formation involves a chemical alteration of the drug molecule, whereas cyclodextrin complexation relies on the formation of inclusion complexes. Understanding the distinct advantages and challenges of each approach is essential for selecting the most appropriate strategy for omeprazole and similar drugs.^65-67

Stability Considerations:

· Chemical Stability of Omeprazole Salts: The stability of omeprazole salts is a critical aspect of their viability for pharmaceutical formulations. Omeprazole sodium, for instance, should maintain its chemical integrity under various storage conditions to ensure the long-term stability of the drug product. Stability studies are crucial in assessing the potential for degradation or other chemical changes in omeprazole salts over time.⁶⁸

· Storage and Handling Considerations: Proper storage and handling conditions play a pivotal role in maintaining the stability of omeprazole salts. Factors such as temperature, humidity, and exposure to light can impact the stability of the salt form. Formulators must carefully consider these parameters to ensure the quality and shelf-life of omeprazole formulations containing salts.

Future Directions and Challenges:

· Exploration of Novel Counterions: While omeprazole sodium has shown promise in improving solubility, ongoing research explores the potential of novel counterions for salt formation. Exploring a broader range of counterions may lead to the discovery of salts with even higher solubility and improved formulation characteristics.⁶⁹

· Combination Approaches: Combining salt formation with other solubility enhancement strategies presents an exciting avenue for future research. The synergistic effects of salt formation with techniques like solid dispersion or nanosizing could result in formulations with enhanced solubility and improved therapeutic performance.^59-61

Salt formation stands as a valuable strategy in enhancing the solubility and dissolution properties of omeprazole. By chemically modifying the drug molecule, salt formation addresses the inherent challenges of poor water solubility. Omeprazole salts, particularly omeprazole sodium, have demonstrated enhanced solubility, faster dissolution rates, and improved bioavailability. As research in this field advances, the exploration of novel counterions and combination approaches holds promise for further optimizing omeprazole formulations and expanding the repertoire of strategies available to pharmaceutical scientists.

Micellar Delivery Systems:

Micellar delivery systems represent an innovative approach to addressing the solubility challenges associated with poorly water-soluble drugs like omeprazole. These systems rely on surfactants to form micellar structures, where the hydrophobic core of the micelle can solubilize lipophilic drugs, enhancing their bioavailability.^70,71

Surfactant Selection for Omeprazole:

In the context of omeprazole, which exhibits lipophilic properties, the choice of surfactant is critical. Surfactants such as sodium dodecyl sulfate (SDS), Tween series, and polymeric surfactants have been explored for their ability to form stable micellar structures and improve the solubility of omeprazole in aqueous environments.⁷¹

Mechanism of Micellar Solubilization:

Micellar delivery systems enhance the solubility of omeprazole by encapsulating the drug molecules within the hydrophobic core of the micelles. This solubilization process facilitates the dispersion of omeprazole in the gastrointestinal fluids, ensuring better absorption in the aqueous environment of the digestive tract.

The enhanced solubility achieved through micellar solubilization directly contributes to improved bioavailability. As omeprazole is released from the micellar structures in the gastrointestinal tract,it encounters less resistance to dissolution, resulting in higher concentrations available for absorption. This mechanism optimizes the therapeutic effects of omeprazole, making micellar delivery systems a promising strategy for formulation development.⁷²

Stability and Formulation Considerations:

· Stability of Micellar Delivery Systems: The stability of micellar delivery systems is crucial for their practical application. Factors such as pH, temperature, and the presence of ions can influence the stability of micelles. Stability studies are essential to understand the performance of micellar delivery systems under various physiological conditions and storage parameters.^73-74

· Formulation Flexibility: Micellar delivery systems offer formulation flexibility due to the variety of surfactants and co-solvents that can be employed. Formulators can tailor the composition of micellar formulations to achieve specific characteristics, such as controlled release or targeted delivery, depending on the therapeutic goals for omeprazole.⁷⁵

Comparative Analysis with Other Strategies:

· Solid Dispersion and Nanosizing vs. Micellar Delivery Systems: Comparing micellar delivery systems with other solubility enhancement strategies reveals distinct differences. While solid dispersion and nanosizing focus on physical modifications of the drug, micellar delivery systems involve the formation of colloidal structures. The choice between these strategies depends on factors such as the nature of the drug, the desired release profile, and considerations for formulation development.⁷⁶

· Cyclodextrin Complexation vs. Micellar Delivery Systems: Similarly, comparing micellar delivery systems with cyclodextrin complexation highlights differences in their mechanisms and outcomes. While both strategies aim to improve drug solubility, micellar delivery systems rely on the formation of micelles to enhance solubility, whereas cyclodextrin complexation involves the formation of inclusion complexes. Understanding the unique advantages and challenges of each approach is essential for selecting the most appropriate strategy for omeprazole and similar drugs.^68,72

Future Directions:

· Exploration of Novel Surfactants: Ongoing research is focused on exploring novel surfactants with enhanced solubilizing capabilities for lipophilic drugs like omeprazole. Tailoring surfactant structures to optimize micellar formation and drug solubilization is a promising avenue for further improving the performance of micellar delivery systems.

· Combination Approaches with Nanotechnology: Combining micellar delivery systems with other nanotechnology approaches, such as nanocrystals or nanoemulsions, presents an exciting area for future research.⁷⁷ These combination approaches may offer synergistic effects, providing enhanced solubility and controlled release for omeprazole formulations.

Micellar delivery systems represent a promising strategy for enhancing the solubility and bioavailability of omeprazole. Leveraging surfactants to form micelles allows for the efficient solubilization of lipophilic drugs in the gastrointestinal fluids, optimizing drug absorption. As research in micellar delivery systems advances, the exploration of novel surfactants, formulation flexibility, and combination approaches with other nanotechnologies hold significant potential for further improving omeprazole formulations and expanding the toolkit of solubility enhancement strategies in pharmaceutical development.⁷⁸

CONCLUSION:

The solubility enhancement of omeprazole stands at the intersection of diverse strategies, each offering unique insights and potential for improved therapeutic outcomes. Solid dispersion technology, with its emphasis on dispersing omeprazole within hydrophilic carriers, showcases versatility in formulation and controlled release. Nanosizing techniques, including nanocrystals and nanoemulsions, address solubility challenges by reducing particle size, augmenting surface area, and optimizing drug release.

Cyclodextrin complexation, through the formation of inclusion complexes, capitalizes on the unique structure of cyclodextrins to enhance omeprazole's solubility and stability. Salt formation, a chemical modification strategy, yields omeprazole salts like omeprazole sodium, demonstrating heightened solubility and dissolution profiles. Micellar delivery systems, reliant on surfactants to form micelles, represent an innovative avenue for solubilizing lipophilic drugs like omeprazole, showing promise in gastrointestinal absorption.

Comparative analyses highlight the need for tailored approaches based on formulation goals and the specific characteristics of omeprazole. Stability considerations and future directions underscore the ongoing pursuit of novel surfactants, combination approaches, and personalized drug delivery strategies.

The implications for clinical translation emphasize the importance of robust in vivo studies and well-designed clinical trials to validate the safety, efficacy, and patient outcomes associated with enhanced omeprazole formulations. Formulation scientists play a pivotal role in bridging the gap between research findings and practical applications, considering scalability and flexibility in formulation development. the multifaceted approach to omeprazole solubility enhancement represents a paradigm shift in pharmaceutical research. As the field continues to evolve, these lessons pave the way for advancements in drug delivery and patient-centric formulations, offering a blueprint for addressing solubility challenges in other poorly water-soluble drugs. The journey from laboratory discovery to clinical impact requires ongoing collaboration, innovation, and a commitment to advancing pharmaceutical science for the benefit of patients worldwide.

REFERENCE:

1. Li W, Zeng S, Yu LS, Zhou Q. Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag. 2013; 9: 259-71. PMID: 23745048; doi: 10.2147/TCRM.S43151.

2. Huang JQ, Hunt RH. pH, healing rate and symptom relief in acid-related diseases. Yale J Biol Med. 1996; 69: 159–174.

3. The American Society of Health-System Pharmacists. Archived from the original on 19 February 2011. Retrieved 21 October 2018.

4. Sachs G, Wallmark B. The gastric H+, K+-ATPase: the site of action of omeprazole. Scand J Gastroenterol Suppl. 1989; 166:3-11.

5. Hassall E Barrett’s esophagus: new definitions and approaches in children. J Pediatr Gastroenterol Nutr. 1993; 16: 345-364.

6. Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther. 1998 Sep; 12(9):893-7.

7. Wallmark B, Lindberg P: Mechanism of action of omeprazole. ISIS Atlas Pharmacol 1:158–160, 1987.

8. Narkhede, Pavan S., Namrata Singh, and Neetesh K. Jain. "Formulation And Characterization Of Immediate Release Solid Dosage Forms Of Omeprazole." Journal of Pharmaceutical Negative Results (2022): 4879-4883.

9. Haeney, M.R., 1992. Angio-edema and urticaria associated with omeprazole. BMJ: British Medical Journal, 305(6858), p.870.

10. Galindo, P.A., Borja, J., Feo, F., Gómez, E., Garcia, R., Cabrera, M. and Martinez, C.,. Anaphylaxis to omeprazole. Annals of Allergy, Asthma & Immunology. 1999; 82(1): 52-54.

11. Ghatan, P.H., Marcusson‐Ståhl, M., Matura, M., Björkheden, C., Lundborg, P. and Cederbrant, K., Sensitization to omeprazole in the occupational setting. Contact Dermatitis. 2014; 71(6): 371-375.

12. Kanagaratham, C., El Ansari, Y.S., Sallis, B.F., Hollister, B.M.A., Lewis, O.L., Minnicozzi, S.C., Oyoshi, M.K., Rosen, R., Nurko, S., Fiebiger, E. and Oettgen, H.C., Omeprazole inhibits IgE-mediated mast cell activation and allergic inflammation induced by ingested allergen in mice. Journal of Allergy and Clinical Immunology. 2020; 146(4): 884-893.

13. Darrow, J.J., Chong, J.E. and Kesselheim, A.S.,. Reconsidering the scope of US state laws allowing pharmacist substitution of generic drugs. BMJ. 2020; 369.

14. Xie, C., Liu, L., Zhu, S. and Wei, M. Effectiveness and safety of Chinese medicine combined with omeprazole in the treatment of gastric ulcer: A protocol for systematic review and meta-analysis. Medicine. 2021; 100(17).

15. Neuman, R.I., Baars, M.D., Saleh, L., Broekhuizen, M., Nieboer, D., Cornette, J., Schoenmakers, S., Verhoeven, M., Koch, B.C., Russcher, H. and van den Berg, S.A., Omeprazole administration in preterm preeclampsia: a randomized controlled trial to study its effect on sFlt-1 (soluble Fms-like tyrosine Kinase-1), PlGF (placental growth factor), and ET-1 (endothelin-1). Hypertension. 2022; 79(6): 1297-1307.

16. Llinas, A., Oprisiu, I. and Avdeef, A.,. Findings of the second challenge to predict aqueous solubility. Journal of Chemical Information and Modeling. 2020; 60(10): 4791-4803.

17. Van Nguyen, H., Baek, N. and Lee, B.J. Enhanced gastric stability of esomeprazole by molecular interaction and modulation of microenvironmental pH with alkalizers in solid dispersion. International Journal of Pharmaceutics. 2017; 523(1):.189-202.

18. Pyo, Y.C., Nguyen, T.N., Lee, Y.S., Choi, Y.E. and Park, J.S. Design of esomeprazole solid dispersion for improved dissolution and bioavailability using the supercritical anti-solvent technique. Journal of Drug Delivery Science and Technology. 2023; 88: p.104889.

19. El-Badry, M. Comparative study of preparation and characterization of enteric and enhanced release omeprazole microparticles. Journal of Drug Delivery Science and Technology, 2011; 21(6): 491-496.

20. Chachlioutaki, K., Iordanopoulou, A., Bouropoulos, N., Meikopoulos, T., Gika, H., Ritzoulis, C., Andreadis, D., Karavasili, C. and Fatouros, D.G. Pediatric and Geriatric-Friendly Buccal Foams: Enhancing Omeprazole Delivery for Patients Encountering Swallowing Difficulties. Journal of Pharmaceutical Sciences. 2023; 112(10): 2644-2654.

21. Trimukhe, A., Rojekar, S., Vavia, P.R. and Deshmukh, R.R. Pulsed plasma surface modified omeprazole microparticles for delayed release application. Journal of Drug Delivery Science and Technology. 2021; 66: 102905.

22. Bunlung, S., Nualnoi, T., Issarachot, O. and Wiwattanapatapee, R. Development of raft-forming liquid and chewable tablet formulations incorporating quercetin solid dispersions for treatment of gastric ulcers. Saudi Pharmaceutical Journal. 2021; 29(10): 1143-1154.

23. Al-Nimry, S.S., Alkhamis, K.A. and Altaani, B.M. Solid self-nanoemulsifying drug delivery system filled in enteric coated hard gelatin capsules for enhancing solubility and stability of omeprazole hydrochloride. Pharmaceutical Development and Technology. 2020; .25(5): 588-600.

24. Halder, S., Tabata, A., Seto, Y., Sato, H. and Onoue, S. Amorphous solid dispersions of carvedilol along with pH‐modifiers improved pharmacokinetic properties under hypochlorhydoria. Biopharmaceutics and Drug Disposition, 2018; 39(4): 232-242.

25. Rouaz-El Hajoui, K., Herrada-Manchón, H., Rodríguez-González, D., Fernández, M.A., Aguilar, E., Suné-Pou, M., Nardi-Ricart, A., Pérez-Lozano, P. and García-Montoya, E.,. Pellets and gummies: Seeking a 3D printed gastro-resistant omeprazole dosage for paediatric administration. International Journal of Pharmaceutics. 2023; 643: 123289.

26. Negi, P., Gautam, S., Sharma, A., Rathore, C., Sharma, L., Upadhyay, N., Tambuwala, M.M., Chellappan, D.K., Gupta, G., Prasher, P. and Dua, K. Gastric ulcer healing by chebulinic acid solid dispersion-loaded gastroretentive raft systems: preclinical evidence. Therapeutic Delivery. 2022; 13(2):.81-93.

27. Gupta, K.M., Chin, X. and Kanaujia, P. Molecular Interactions between APIs and Enteric Polymeric Excipients in Solid Dispersion: Insights from Molecular Simulations and Experiments. Pharmaceutics. 2023; 15(4): 1164.

28. Peralta, C.M., Fernández, L.P. and Masi, A.N. Precision improvement for omeprazole determination through stability evaluation. Drug Testing and Analysis. 2012; 4(1):.48-52.

29. Trimukhe, A., Rojekar, S., Vavia, P.R. and Deshmukh, R.R. Pulsed plasma surface modified omeprazole microparticles for delayed release application. Journal of Drug Delivery Science and Technology. 2021; 66: 102905.

30. 8Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010; 59: 1143–53.

31. Srebro, J., Brniak, W. and Mendyk, A. Formulation of dosage forms with proton pump inhibitors: state of the art, challenges and future perspectives. Pharmaceutics. 2022; 14(10): 2043.

32. Bell, N. J., Burget, D., Howden, C. W., Wilkinson, J. and Hunt, R. H. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992; 51(Suppl. 1): 59–67.

33. Vojčić, N., Bregović, N., Cindro, N., Požar, J., Horvat, G., Pičuljan, K., Meštrović, E. and Tomišić, V. Optimization of Omeprazole Synthesis: Physico‐Chemical Steering Towards Greener Processes. Chemistry Select. 2017; 2(17): 4899-4905.

34. Klieber, M., Oberacher, H., Hofstaetter, S., Beer, B., Neururer, M., Amann, A., Alber, H. and Modak, A. CYP2C19 phenoconversion by routinely prescribed proton pump inhibitors omeprazole and esomeprazole: clinical implications for personalized medicine. Journal of Pharmacology and Experimental Therapeutics. 2015; 354(3): 426-430.

35. Al-Nimry, S.S., Alkhamis, K.A. and Altaani, B.M. Solid self-nanoemulsifying drug delivery system filled in enteric coated hard gelatin capsules for enhancing solubility and stability of omeprazole hydrochloride. Pharmaceutical Development and Technology. 2020; 25(5): 588-600.

36. Gupta, M.K., Sreedharan, S.K. and Sajeeth, C.I. Design development and characterization of omeprazole loaded nanosuspension. Journal of Pharmaceutical Negative Results, 2022: 1195-1208.

37. Rezazadeh, M., Safaran, R., Minaiyan, M. and Mostafavi, A. Preparation and characterization of Eudragit L 100-55/chitosan enteric nanoparticles containing omeprazole using general factorial design: in vitro/in vivo study. Research in Pharmaceutical Sciences. 2021; 16(4): 358.

38. Ramteke, S. and Jain, N.K. Clarithromycin-and omeprazole-containing gliadin nanoparticles for the treatment of Helicobacter pylori. Journal of Drug Targeting. 2008; 16(1):.65-72.

39. Le Merdy, M., Tan, M.L., Sun, D., Ni, Z., Lee, S.C., Babiskin, A. and Zhao, L. Physiologically based pharmacokinetic modeling approach to identify the drug–drug interaction mechanism of Nifedipine and a proton pump inhibitor, Omeprazole. European Journal of Drug Metabolism and Pharmacokinetics. 2021; 46: 41-51.

40. Murakami, F.S., Lang, K.L., Mendes, C., Cruz, A.P., Carvalho Filho, M.A. and Silva, M.A. Physico-chemical solid-state characterization of omeprazole sodium: thermal, spectroscopic and crystallinity studies. Journal of Pharmaceutical and Biomedical Analysis. 2009; 49(1): 72-80.

41. Gao, H., Song, Y., Ma, J., Zhai, J., Zhang, Y. and Qu, X. Untargeted metabolomics analysis of omeprazole-enhanced chemosensitivity to cisplatin in mice with non-small cell lung cancer. Chemico-Biological Interactions. 2022; 360: 109933.

42. Gupta, M.K., Sreedharan, S.K. and Sajeeth, C.I., Design development and characterization of omeprazole loaded nanosuspension. Journal of Pharmaceutical Negative Results. 2022; 1195-1208.

43. Boscolo, O., Perra, F., Salvo, L., Buontempo, F. and Lucangioli, S. Formulation and stability study of omeprazole oral liquid suspension for pediatric patients. Hospital Pharmacy. 2020; 55(5): 314-322.

44. Yadollahi, R., Vasilev, K. and Simovic, S., 2015. Nanosuspension technologies for delivery of poorly soluble drugs. Journal of Nanomaterials. 2015: 1-1.

45. Bestebreurtje, P., Roeleveld, N., Knibbe, C.A., van Sorge, A.A., Plötz, F.B. and de Wildt, S.N. Development and stability study of an omeprazole suppository for infants. European Journal of Drug Metabolism and Pharmacokinetics. 2020; 45: 627-633.

46. Neishi, M., Hamano, H., Niimura, T., Denda, M., Yagi, K., Miyata, K., Lin, T.J., Higashionna, T., Goda, M., Zamami, Y. and Ishizawa, K. Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases. Toxicology and Applied Pharmacology. 2023; 475: 116632.

47. Sardesai, S.D., Thomas, A., Gallagher, C., Lynce, F., Ottaviano, Y.L., Ballinger, T.J., Schneider, B.P., Storniolo, A.M., Bauchle, A., Althouse, S.K. and Perkins, S.M. Inhibiting fatty acid synthase with omeprazole to improve efficacy of neoadjuvant chemotherapy in patients with operable TNBC. Clinical Cancer Research, 2021; 27(21): 5810-5817.

48. Arias, M.J., Arias-Blanco, M.J., Moyano, J.R., Muñoz, P., Gines, J.M., Justo, A. and Giordano, F. Study of omeprazole-γ-cyclodextrin complexation in the solid state. Drug Development and Industrial Pharmacy. 2000; 26(3): 253-259.

49. Sultana, T., Jung, J.M., Hong, S.S., Lee, W.K., Gal, Y.S., Kim, H.G. and Lim, K.T. Characteristic profiles of the inclusion complex of omeprazole/peracylated-β-cyclodextrin formed in supercritical carbon dioxide. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2012; 72: 207-212.

50. Setiadji, S., Sundari, C.D.D., Nuryadin, B.W., Zayyinunnisya, H., Cahyandari, R. and Ivansyah, A.L. September. Computational Study of Inclusion Complexes Between Omeprazole Enantiomer with Hydroxypropyl-β-Cyclodextrin. In Journal of Physics: Conference Series. 2018; 1090(1): 12055

51. Bestebreurtje, P., Roeleveld, N., Knibbe, C.A., van Sorge, A.A., Plötz, F.B. and de Wildt, S.N. Development and stability study of an omeprazole suppository for infants. European Journal of Drug Metabolism and Pharmacokinetics. 2020; 45: 627-633.

52. Strotmann, R., Heuer, J., Becker, A., Krebs-Brown, A., Mammasse, N. and Yalkinoglu, Ö. Bioavailability of tepotinib: impact of omeprazole and food. Annals of Oncology. 2019; 30: 182.

53. Washington, C., Hou, E., Hughes, N. and Berner, B. Effect of omeprazole on bioavailability of an oral extended-release formulation of ciprofloxacin. American Journal of Health-System Pharmacy. 2006; 63(7): 653-656.

54. Spénard, J., Aumais, C., Massicotte, J., Tremblay, C. and Lefebvre, M. Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. The Journal of Clinical Pharmacology. 2004; 44(6): 640-645.

55. Arias, M.J., Arias-Blanco, M.J., Moyano, J.R., Muñoz, P., Gines, J.M., Justo, A. and Giordano, F. Study of omeprazole-γ-cyclodextrin complexation in the solid state. Drug Development and Industrial Pharmacy. 2000; 26(3): 253-259.

56. Cross, L.B. and Justice, L.N. Combination drug therapy for gastroesophageal reflux disease. Annals of Pharmacotherapy. 2002; 36(5): 912-916.

57. Freston, J.W. Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. American Journal of Gastroenterology (Springer Nature). 1997: 92.

58. Setiadji, S., Sundari, C.D.D., Ramdhani, M.A., Umam, A.B.K. and Ivansyah, A.L. Theoretical investigation of inclusion complex between omeprazole enantiomers and carboxymethyl-β-cyclodextrin. In IOP Conference Series: Materials Science and Engineering. 2018; 288(1); 12138.

59. Ferreira, J. and Moss, S.F. Current paradigm and future directions for treatment of Helicobacter pylori infection. Current Treatment Options in Gastroenterology. 2014; 12: 373-384.

60. Figueiras, A., Carvalho, R.A., Ribeiro, L., Torres-Labandeira, J.J. and Veiga, F.J. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified β-cyclodextrin. European Journal of Pharmaceutics and Biopharmaceutics. 2007; 67(2): 531-539.

61. Åsberg, D., Leśko, M., Samuelsson, J., Karlsson, A., Kaczmarski, K. and Fornstedt, T. Combining chemometric models with adsorption isotherm measurements to study omeprazole in RP-LC. Chromatographia. 2016; 79: 1283-1291.

62. Vrbanec, T., Šket, P., Merzel, F., Smrkolj, M. and Grdadolnik, J. Spectroscopic characterization of omeprazole and its salts. Journal of Spectroscopy. 2017.

63. Shastry, V., Ramyashree, H. and Ravindra, K. Kinetics and mechanism of oxidation of omeprazole by potassium ferrate. International Journal of Medicince and Pharmaceutical Science. 2019; 9: 9-18.

64. Rajana, Nagaraju. Srikanth, B., Ramana, D.V., Yarbagi, K.M., Madhavan, P., Babu, J.M., Basavaiah, K. and Devi, D.R. Simultaneous Determination of Sodium, Potassium and Magnesium Counter Ions in Three Drugs: Pantoprazole Sodium, Losartan Potassium and Omeprazole Magnesium by Ion Chromatography. Asian J Chemistry. 2018; 30(9): 2022-2028.

65. Strotmann, R., Heuer, J., Becker, A., Krebs-Brown, A., Mammasse, N. and Yalkinoglu, Bioavailability of tepotinib: impact of omeprazole and food. Annals of Oncology. 2019; 30: 182.

66. Figueiras, A., Carvalho, R.A., Ribeiro, L., Torres-Labandeira, J.J. and Veiga, F.J. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified β-cyclodextrin. European Journal of Pharmaceutics and Biopharmaceutics. 2007; 67(2): 531-539.

67. Zheng, R.N. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World Journal of Gastroenterology. 2009; 15(8): 990.

68. Boscolo, O., Perra, F., Salvo, L., Buontempo, F. and Lucangioli, S. Formulation and stability study of omeprazole oral liquid suspension for pediatric patients. Hospital Pharmacy. 2020; 55(5): 314-322.

69. Klein, L.L. and Tanaka, S.K. Therapy of Helicobacter pylori infections: Current status and future directions. Annual Reports in Medicinal Chemistry. 1995; 30: 151-158.

70. Al-Nimry, S.S., Alkhamis, K.A. and Altaani, B.M. Solid self-nanoemulsifying drug delivery system filled in enteric coated hard gelatin capsules for enhancing solubility and stability of omeprazole hydrochloride. Pharmaceutical Development and Technology. 2020; 25(5): 588-600.

71. Al-Nimry, S.S., Alkhamis, K.A. and Altaani, B.M. Solid self-nanoemulsifying drug delivery system filled in enteric coated hard gelatin capsules for enhancing solubility and stability of omeprazole hydrochloride. Pharmaceutical Development and Technology. 2020; 25(5): 588-600.

72. Lopes-de-Campos, D., Pereira-Leite, C., Fontaine, P., Coutinho, A., Prieto, M., Sarmento, B., Jakobtorweihen, S., Nunes, C. and Reis, S. Interface-Mediated Mechanism of Action—The Root of the Cytoprotective Effect of Immediate-Release Omeprazole. Journal of Medicinal Chemistry. 2021; 64(8): 5171-5184.

73. Sinly, C., Saito, H., Anorach, R., Uramaru, N., Kaku, T., Benchawattananon, R., Navanukraw, C., Panomsuk, S., Kubota, Y. and Rittirod, T., Stability consideration in extemporaneous omeprazole suspension.

74. Cong, Y., Geng, J., Wang, H., Su, J., Arif, M., Dong, Q., Chi, Z. and Liu, C. Ureido-modified carboxymethyl chitosan-graft-stearic acid polymeric nano-micelles as a targeted delivering carrier of clarithromycin for Helicobacter pylori: Preparation and in vitro evaluation. International journal of biological macromolecules. 2019; 129: 686-692.

75. Aubert, J., Mulder, C.J., Schrör, K. and Vavricka, S.R. Omeprazole Mups®: An advanced formulation offering flexibility and predictability for self medication-Selfcare Journal. SelfCare Journal. 2015.

76. Zheng, R.N. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World Journal of Gastroenterology. 2009; 15(8): 990.

77. Markovic-Pekovic, V., Škrbić, R., Godman, B. and Gustafsson, L.L. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Review of Pharmacoeconomics and Outcomes Research, 2012; 12(5): 661-671.

78. Franciosi, J.P., Mougey, E.B., Dellon, E.S., Gutierrez-Junquera, C., Fernandez-Fernandez, S., Venkatesh, R.D. and Gupta, S.K. Proton pump inhibitor therapy for eosinophilic esophagitis: history, mechanisms, efficacy, and future directions. Journal of Asthma and Allergy. 2022: 281-302.

Received on 12.12.2023 Modified on 04.02.2024

Res. J. Pharma. Dosage Forms and Tech.2024; 16(2):163-172.

DOI: 10.52711/0975-4377.2024.00026